Topical and oral bexarotene

Dermatologic Therapy

Volumn 26, Issue 5, 2013, Pages 400-403

  Schadt, Courtney R ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

bexarotene; cutaneous T cell lymphoma; retinoids

Indexed keywords

ALPHA INTERFERON; BEXAROTENE; GEMFIBROZIL; LEVOTHYROXINE;

ARTICLE; ASTHENIA; CUTANEOUS T CELL LYMPHOMA; DERMATITIS; DIARRHEA; DRUG BINDING; DRUG DOSE TITRATION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HUMAN; HYPERLIPIDEMIA; HYPOTHYROIDISM; NAUSEA; NEUTROPENIA; PRURITUS; SIDE EFFECT;

BEXAROTENE; CUTANEOUS T CELL LYMPHOMA; RETINOIDS;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTICARCINOGENIC AGENTS; DRUG APPROVAL; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES;

EID: 84885439300     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12087     Document Type: Article

References (31)

1. Mangelsdorf DJ, Borgmeyer U, Heyman RA, et al. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev 1992: 6: 329-344.
2. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM,. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992: 358: 771-774.
3. Zhang C, Duvic M,. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol Ther 2003: 16: 322-330.
4. Scarisbrick JJ, Morris S, Azurdia R, et al. UK consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol 2013: 168: 192-200.
5. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M,. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002: 8: 1234-1240.
6. Budgin JB, Richardson SK, Newton SB, et al. Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol 2005: 141: 315-321.
7. Nieto-Rementeria N, Perez-Yarza G, Boyano MD, et al. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol 2009: 160: 519-526.
8. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001: 137: 581-593.
9. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001: 19: 2456-2471.
10. Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M,. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002: 47: 672-684.
11. McGinnis KS, Shapiro M, Vittorio CC, Rook AH, Junkins-Hopkins JM,. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: an effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. Arch Dermatol 2003: 139: 771-775.
12. McGinnis KS, Junkins-Hopkins JM, Crawford G, Shapiro M, Rook AH, Vittorio CC,. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol 2004: 50: 375-379.
13. Foss F, Demierre MF, DiVenuti G,. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005: 106: 454-457.
14. Kannangara AP, Levitan D, Fleischer AB Jr,. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma. J Dermatolog Treat 2009: 20: 169-176.
15. Straus DJ, Duvic M, Kuzel T, et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 2007: 109: 1799-1803.
16. Schlaak M, Kurschat P, Shimabukuro-Vornhagen A, et al. Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation. Transpl Immunol 2011: 25: 163-166.
17. Mehta N, Wayne AS, Kim YH, et al. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clin Lymphoma Myeloma Leuk 2012: 12: 20-25.
18. Muniesa C, Estrach T, Pujol RM, et al. Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases. J Am Acad Dermatol 2010: 62: 418-426.
19. Oliveira A, Fernandes I, Alves R, Lima M, Selores M,. Primary cutaneous CD30 positive anaplastic large cell lymphoma-report of a case treated with bexarotene. Leuk Res 2011: 35: e190-e192.
20. Smit JV, Franssen ME, de Jong EM, et al. A phase II multicenter clinical trial of systemic bexarotene in psoriasis. J Am Acad Dermatol 2004: 51: 249-256.
21. Musolino A, Panebianco M, Zendri E, Santini M, Di Nuzzo S, Ardizzoni A,. Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids. Br J Haematol 2009: 145: 84-86.
22. Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999: 340: 1075-1079.
23. Hespel A, Mejdoubi-Charef N, Yous S, Courty J, Papy-Garcia D, Charef S,. Interactions of bexarotene (LGD1069, Targretin) with the coagulation system. Cancer Chemother Pharmacol 2011: 68: 847-854.
24. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ,. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002: 138: 325-332.
25. Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD,. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 2003: 49: 801-815.
26. Hanifin JM, Stevens V, Sheth P, Breneman D,. Novel treatment of chronic severe hand dermatitis with bexarotene gel. Br J Dermatol 2004: 150: 545-553.
27. Breneman D, Sheth P, Berger V, Naini V, Stevens V,. Phase II clinical trial of bexarotene gel 1% in psoriasis. J Drugs Dermatol 2007: 6: 501-506.
28. Talpur R, Vu J, Bassett R, Stevens V, Duvic M,. Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. J Am Acad Dermatol 2009: 61: 592 e1-592 e9.
29. Krathen RA, Ward S, Duvic M,. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology 2003: 206: 142-147.
30. Magliocco MA, Pandya K, Dombrovskiy V, Christiansen L, Wong Y, Gottlieb AB,. A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2006: 54: 115-118.
31. Walling HW, Swick BL, Gerami P, Scupham RK,. Folliculotropic mycosis fungoides responding to bexarotene gel. J Drugs Dermatol 2008: 7: 169-171.